Microbiota contribute to skin damage in cancer therapy

New research demonstrates that disruption of EGF receptor signalling allows commensal bacteria to invade hairs and cause skin lesions.

Read more

BIOncoTech Therapeutics and MSD combine cancer drugs

Madrid-based RNA specialist Bioncotech Therapeutics has entered into a Phase II clinical trial collaboration with a MSD subsidiary.

Read more

Urokinase clears blot clots in stroke patients

Swiss surgeons have significantly improved mechanical removal of blood clots in stroke patients by intra-arterial administration of the thromolytic urokinase.

Read more

Sanofi buys Synthorx Inc for US$2.35bn

Sanofi will acquire Synthorx Inc to expand its  immuno-oncology pipeline with THOR-707, an optimised IL-2 candidate.

Read more

Meatable NV raises US$10m in seed funding

Meatable NV, a specialist for cultivated meat, has raised an additional US$10m in seed funding, bringing the company’s total funding to US$13m.

Read more

Big Pharma is cost driver of GAVI

Médecins Sans Frontières (MSF) called on the GAVI Vaccine Alliance not to pay huge subsidies to Big Pharma companies for pneumococcal vaccine

Read more

ImCheck Therapeutics SAS raises €48m

T cell agonist specialist ImCheck Therapeutics will use €48m (US$53m) from a Series B financing to push clincial pipeline of antibodies activating gamma-delta T-cells.

Read more

Pierre Fabre amends license agreement with Puma Biotechnology

Pierre Fabre SA and Puma Biotechnology, Inc. have broadened the geographic coverage of their license agreement on commercialisation of Nerlynx® (neratinib).

Read more

European circular bioeconomy fund near closing

The European Commission and the European Investment Bank (EIB) have selected ECBF Management GmbH as investment advisor for the €250m EU circular bioeconomy fund.

Read more

Researchers find new indication for cancer drug

French researchers have found MALT1 blockers not only to act on blood cancers but also to be effective as a treatment for glioblastoma. 

Read more